Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British medical research council multicenter randomized trial
N. Thatcher et al., Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British medical research council multicenter randomized trial, J CL ONCOL, 18(2), 2000, pp. 395-404
Purpose: The treatment of small-cell lung cancer patients with good perform
ance status aims to improve survival. Dose-intensification could be a way t
o achieve improved survival but can be limited by neutropenia and thrombocy
topenia. Preliminary, nonrandomized feasibility studies showed that doxorub
icin, cyclophosphamide, and etoposide (ACE) could be given every 2 (instead
of the usual 3) weeks with granulocyte colony-stimulating factor (G-CSF) (
lenograstim; Chugai-Rhone-Poulenc. Tokyo, Japan) support. The present multi
center randomized trial was designed to examine whether such dose-intensifi
cation improves survival while maintaining acceptable toxicity levels.
Patients and Methods: All patients were randomized to receive six cycles of
ACE either every 3 weeks (control [C] group) or every 2 weeks with G-CSF (
G group). The standard dose-intensity of ACE was increased by 50% in group
G.
Results: Four hundred and three patients (G group: group: n = 202) were ran
domized. The received dose-intensity was 34% higher in the G group than in
the C group, Complete response rates were 40% for the G group and 28% for t
he C group (P = .02), and overall rates were 78% for the G group and 79% fo
r the C group. Survival was longer in the G group (hazard ratio = 0.80; 95%
confidence interval, 0.65 to 0.99; P =.04), survival rates for the G and C
groups being 47% and 39% at 12 months and 13% and 8% at 24 months, respect
ively. Metastasis-free survival, nonhematologic toxicity, and quality of li
fe were similar in the two groups. In the G group, there was less neutropen
ia but more thrombocytopenia and more frequent blood and platelet transfusi
ons.
Conclusion: Increasing the dose-intensity of ACE with G-CSF support improve
d survival while maintaining acceptable toxicity. (C) 2000 by American Soci
ety of Clinical Oncology.